Category: Health

The 2024-2025 COVID-19 vaccine may reduce serious cardiovascular events among U.S. veterans, particularly those aged 75 and older, according to new research.

New research has linked the 2024-2025 COVID-19 vaccine to a reduction in serious cardiovascular events among U.S. veterans, especially those over the age of 75.

The study indicates a small decrease in COVID-related cardiovascular events, known as COVID-19-associated major adverse cardiovascular events (MACE), attributed to the vaccine. MACE is a composite measure that typically includes serious heart-related outcomes such as cardiovascular death, heart attack, stroke, and may also encompass hospitalization for heart failure.

Researchers utilized health records from the U.S. Department of Veterans Affairs to compare two groups of veterans: one group that received both the COVID-19 and flu vaccines on the same day, comprising nearly 350,000 individuals, and another group that received only the flu vaccine, totaling nearly 700,000 people. The study analyzed over one million veterans, with an average age of about 70, and 92% of the participants were male, according to a press release.

Results from the study revealed that within approximately eight months, those who received the 2024-2025 COVID vaccine exhibited a lower risk of COVID-associated major cardiovascular events, with a relative vaccine effectiveness of 37.7%. Specifically, the COVID vaccine was associated with a 57.9% lower risk of cardiovascular death, a 38.5% lower risk of heart attack, and a 41.9% lower risk of hospitalization for heart failure. However, the results concerning stroke were not statistically significant.

The benefits of the vaccine were most pronounced among older adults, particularly those aged 75 and older, where the vaccine demonstrated an effectiveness of 50.7% in preventing COVID-associated MACE. While the study provides valuable insights, it is important to note that it was observational in nature and could not establish a definitive cause-and-effect relationship between the COVID-19 vaccine and the reduced risk of cardiovascular events.

Dr. Glenn Hirsch, a cardiologist at National Jewish Health in Denver, Colorado, commented on the findings, stating that the results were “not overall surprising.” He noted that these findings align with previous studies examining the COVID-19 vaccine and other vaccines against infectious diseases in preventing cardiovascular events, including heart attacks and cardiovascular-related deaths or hospitalizations.

According to Dr. Hirsch, acute inflammation caused by infections like COVID-19 can elevate the risk of cardiovascular events and lead to further complications. He explained that such inflammation increases the likelihood of blood clotting and makes arterial plaques more susceptible to rupture, which can subsequently lead to clot formation and the occlusion of arteries, resulting in cardiovascular events.

“Vaccines either prevent infection or reduce the severity of infection and subsequent inflammation, thereby lowering cardiovascular risk,” Dr. Hirsch stated.

Despite the positive outcomes observed in this study, Dr. Hirsch noted that the overall benefit of the vaccine was less pronounced compared to previous studies. This discrepancy may be attributed to the lower severity of illness associated with more recent COVID-19 variants, as well as the immunity conferred by prior infections among unvaccinated individuals. Additionally, a decline in COVID-19 testing has made it more challenging to link cardiovascular events directly to the virus.

Dr. Hirsch emphasized the importance of vaccination, stating, “The bottom line is that there is still evidence of benefit from COVID-19 vaccination, similar to many other infectious disease vaccinations. People should be encouraged to discuss these with their healthcare team annually.”

He also cautioned that, as this was an observational trial, there could be confounding factors even after necessary statistical adjustments. Other potential benefits or harms, including adverse effects from vaccines that were not investigated in this study, should also be considered.

As the research continues to unfold, the findings underscore the potential health benefits of the COVID-19 vaccine, particularly for vulnerable populations such as older adults and those with pre-existing health conditions, suggesting a continued role for vaccination in public health strategies.

These insights were reported in a recent press release, highlighting the ongoing importance of vaccination in mitigating health risks associated with COVID-19.

According to Fox News, the findings contribute to the growing body of evidence supporting the benefits of vaccination in reducing serious health complications.

Marius Pharmaceuticals supports the FDA’s proposal to revise testosterone therapy warnings, reflecting new clinical evidence regarding safety and effectiveness for age-related low testosterone.

Marius Pharmaceuticals has expressed its support for a proposal by the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) to update the prescribing information for testosterone replacement therapies. The company believes these changes are a reflection of years of accumulating scientific evidence.

Announced during Men’s Health Month, the proposed revisions aim to remove language indicating that the safety and effectiveness of testosterone therapy for age-related low testosterone had not been established. Additionally, the FDA plans to update information regarding prostate cancer risk and revise warnings related to enlarged prostate conditions.

The FDA stated that these changes are based on a review of newer clinical evidence, which includes a cardiovascular outcomes study involving over 5,200 men. This study found no significant increase in serious cardiovascular events among patients receiving testosterone therapy.

This latest action follows a broader regulatory review that began in 2014, when the FDA issued a safety communication and convened an advisory committee due to concerns about potential cardiovascular risks associated with testosterone therapy. In 2015, the agency imposed restrictions on the use of testosterone products for men with age-related low testosterone due to the limited evidence available at that time.

In February 2025, the FDA removed its boxed warning on cardiovascular risks for testosterone products after reviewing new safety data, but it retained restrictions related to age-related low testosterone. The newly proposed revisions seek to address this remaining language and update warnings related to prostate health.

“This is a defining moment for evidence-based men’s health,” stated Shalin Shah, Chief Executive Officer of Marius Pharmaceuticals. “For years, patients and physicians lacked clear guidance because the evidence was still developing. As more data became available, the findings became increasingly clear, and these updates reflect that progress.”

Shah, who previously presented evidence supporting testosterone therapy at an FDA advisory panel meeting, emphasized that the latest changes reflect the growing body of research in the field. “What changed is not the medicine, but the strength of the evidence,” he noted.

Kyzatrex, developed by Marius Pharmaceuticals, is an FDA-approved treatment for testosterone deficiency based in Raleigh, North Carolina. An estimated 20 million men between the ages of 25 and 75 in the United States suffer from low testosterone. Despite its prevalence, hypogonadism often goes undiagnosed and untreated, which can increase the risk of metabolic disorders, cardiovascular disease, and a diminished quality of life.

Healthcare experts emphasize that addressing testosterone deficiency is crucial not only for improving patients’ well-being but also for reducing the long-term burden of chronic disease. Marius Pharmaceuticals has stated that it will continue to collaborate with healthcare providers and health systems as the FDA moves to align prescribing information with current clinical evidence.

The proposed revisions to testosterone therapy warnings represent a significant step forward in the understanding and treatment of low testosterone, aligning medical practice with the latest scientific findings, according to The American Bazaar.

Shivani, a 58-year-old banking professional, navigates her cataract diagnosis and surgery, shedding light on the condition and the importance of timely intervention for improved vision and quality of life.

Shivani, a 58-year-old banking professional residing in Oregon, was troubled by blurred vision. Having been diabetic for many years, she consulted her ophthalmologist, who informed her that although she did not have diabetic retinopathy, she had cataracts in both eyes and required surgery. Concerned about the diagnosis, especially since she believed cataracts typically develop after the age of 80, Shivani sought advice on how to cope with the upcoming procedure.

According to Dr. Manoj Sharma, a cataract is characterized by the clouding of the lens in the eye, which is normally clear and essential for focusing light. The development of cataracts can lead to blurry vision, visual impairment, and, if untreated, blindness. Globally, approximately 53 million people are affected by blindness due to cataracts, with aging being the primary risk factor; about two-thirds of individuals over 80 years old are affected.

Shivani’s concern about developing cataracts in her 50s is not unfounded. Dr. Sharma explains that risk factors for cataracts include genetic predisposition, certain medications (such as corticosteroids), eye injuries, UV exposure, radiation therapy, and uncontrolled diabetes. Thus, it is indeed possible to develop cataracts at a younger age.

Early cataract surgery can significantly enhance not only vision but also overall quality of life. Improved vision can lead to better physical health by reducing the risk of falls, enhancing cognitive abilities, and alleviating depression.

When asked if surgery was the only option, Dr. Sharma emphasized that cataract surgery is one of the most common and successful surgical procedures performed worldwide, with approximately 4 million surgeries conducted annually in the United States alone. While it is possible to delay surgery, he recommends proceeding with it if advised by a healthcare professional, especially while the patient is in good health.

The outpatient procedure involves the removal of the clouded natural lens using ultrasound waves and suction, followed by the insertion of a clear artificial intraocular lens (IOL). The surgery typically lasts between 10 to 15 minutes and is performed under numbing drops and mild sedation. Most patients notice improved vision within a few days following the procedure.

Preparation for cataract surgery typically involves treating one eye at a time, with at least two weeks between surgeries. Prior to the operation, the ophthalmologist will measure the size and shape of the eye to select the appropriate IOL. There are several types of IOLs available, including monofocal IOLs (which correct one visual field, usually distance), toric IOLs (which also correct astigmatism), multifocal IOLs (which address near, intermediate, and distance vision), extended depth of focus (EDOF) IOLs, and light-adjustable IOLs.

Patients will begin using prescription eye drops to prevent infection and inflammation before the surgery. They may also need to discontinue certain medications that could increase bleeding risks during the procedure. On the day of surgery, it is advisable to have someone accompany the patient to drive them home afterward.

Post-surgery, patients are instructed to continue using the prescribed eye drops for at least two weeks and may need to wear a protective shield over the eye to prevent accidental injury. It is essential to avoid heavy exercise, touching the eye, swimming, and lifting heavy objects during the recovery period.

Dr. Sharma also highlights potential complications to be aware of after surgery, including vision loss, severe pain in the operated eye, excessive redness, or the appearance of small dark spots in vision. While the chances of complications such as eye infections, bleeding, or dislocation of the IOL have decreased over the years, it is still important to monitor for these issues. In some cases, the membrane behind the lens may scar weeks, months, or even years after surgery, but this can be easily corrected with a YAG laser capsulotomy.

While yoga is not a treatment for cataracts, Dr. Sharma notes that meditation and gentle deep breathing can be beneficial for reducing pre-surgical stress and promoting relaxation post-surgery. However, patients should avoid intense physical strain and bending, which can increase eye pressure, for at least two months after the procedure.

For those seeking additional information on cataract surgery, Dr. Sharma recommends several resources, including the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, the Cleveland Clinic, the Mayo Clinic, and the National Eye Institute.

If you have further questions, you can reach out to Dr. Manoj Sharma at editor@indiacurrents.com.

This article highlights the importance of understanding cataracts, their treatment options, and the necessary preparations for surgery, ultimately aiming to improve the quality of life for those affected.

New research suggests that GLP-1 weight loss drugs may enhance male fertility in obese men without suppressing hormones.

GLP-1 medications, such as semaglutide and liraglutide, may offer unexpected benefits for male fertility, according to recent findings presented at the Endocrine Society’s annual meeting, ENDO 2026, in Chicago.

Experts indicate that these weight loss drugs do not appear to suppress male hormones, and instead, they may improve fertility in obese men. Obesity is closely linked to fertility issues in men, as excess weight can disrupt the hypothalamic-pituitary-gonadal (HPG) axis, the hormone system responsible for regulating testosterone production. This disruption can lead to functional hypogonadism, a condition characterized by abnormally low testosterone levels due to impaired hormone signaling, which can also negatively affect semen quality.

The research team evaluated the effects of GLP-1 medications on reproductive hormones and metabolic outcomes by analyzing data from men aged 18 to 65 who were undergoing treatment with these drugs. Their systematic review encompassed five randomized controlled trials that measured testosterone levels, brain hormones involved in testosterone and sperm production, and a protein that transports sex hormones in the bloodstream. Additionally, they assessed semen quality, weight, body mass index (BMI), cholesterol levels, and blood sugar.

The findings indicated that GLP-1 medications do not suppress male hormones. In fact, men with obesity and low testosterone linked to their weight may experience improvements in testosterone levels, sperm quality, and overall metabolic health, particularly during weight loss.

In a four-week study involving dulaglutide, researchers found no significant changes in reproductive hormones or sexual function. Conversely, a separate 16-week trial of liraglutide demonstrated improvements in hormone levels among obese men with functional hypogonadism, suggesting that their low testosterone was likely related to obesity. Notably, liraglutide was found to be more effective for health outcomes compared to traditional hormone replacement therapy.

Another study focusing on liraglutide reported enhancements in sperm concentration and count. Meanwhile, a 24-week trial of semaglutide, marketed as Ozempic and Wegovy, revealed improvements in sperm morphology and reductions in bad cholesterol, all while maintaining total testosterone levels.

Despite these promising results, the authors of the research acknowledged that the evidence base is limited, as only five trials were included in the review. They emphasized the necessity for further research to establish a more definitive association.

In their abstract, the researchers concluded that GLP-1 medications “do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.” However, they also noted that “evidence remains limited and heterogeneous, underscoring the need for larger randomized controlled trials explicitly powered to assess male reproductive outcomes.”

Dr. Anthony Puopolo, a men’s health expert and lead medical provider for RexMD, commented on the findings in an interview, expressing optimism about the implications of GLP-1 medications for improving testosterone levels in obese men with hypogonadism or low testosterone.

“This provides early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone improves testosterone levels,” Dr. Puopolo stated.

While further research is warranted, he highlighted the potential for GLP-1s to serve as a more favorable option for addressing low testosterone in obese men compared to testosterone replacement therapy (TRT), which can adversely affect male reproductive and sperm function.

As the research continues to evolve, the implications of GLP-1 medications on male fertility could reshape treatment approaches for men struggling with obesity and related reproductive health issues, according to Fox News Digital.

New research published in The BMJ questions the effectiveness of calcium and vitamin D supplements in preventing fractures and falls among healthy older adults.

For decades, older adults have been advised to take daily calcium and vitamin D supplements to strengthen their bones and reduce the risk of fractures and falls. However, a significant new systematic review and meta-analysis published in The BMJ challenges this long-standing medical guidance. The study analyzed data from 69 randomized controlled trials involving nearly 154,000 participants, revealing that these widely used supplements may provide little to no clinically meaningful benefit for most older adults in the general population.

The research, conducted by a Canadian team, aimed to clarify the real-world impact of calcium and vitamin D supplementation on bone health. While these nutrients are essential for bone metabolism, the review found that for community-dwelling older adults who are not already receiving treatment for osteoporosis, routine supplementation does not significantly reduce the risk of hip, vertebral, or other fractures.

Moreover, the findings indicated that the supplements do not meaningfully decrease the frequency of falls, which are a major cause of injury and loss of independence among seniors. The researchers concluded, “These findings do not support routine supplementation with calcium or vitamin D, or combined supplementation to prevent fractures and falls.” Given the widespread nature of this practice and the significant increase in supplement prescriptions in recent years, the team is urging clinicians, guideline panels, and regulatory agencies to fundamentally re-evaluate their current recommendations.

Despite the concerning results of the review, health experts stress that these findings should not be interpreted as a blanket dismissal of the importance of calcium and vitamin D. The study authors noted that the results may not apply to individuals with specific bone disorders, those living in high-risk residential care settings, or patients currently undergoing drug treatment for osteoporosis.

Professor Emma L. Duncan of King’s College London emphasized that for patients who have already experienced a fragility fracture or have a confirmed diagnosis of osteoporosis, these nutrients remain crucial for bone health management. “If you are in a higher risk group, you certainly need enough calcium and vitamin D for bone health,” Duncan stated, advising patients to consult their healthcare providers before making any changes to their supplement regimen.

The study’s findings suggest a potential shift in how medical professionals should approach fall and fracture prevention. Rather than relying on a “magic pill” approach, the authors advocate for redirecting focus and funding toward interventions that have demonstrated clearer benefits. Experts increasingly emphasize the importance of “meaningful prevention” strategies, such as targeted balance and resistance training exercises, which help maintain muscle mass, coordination, and overall physical stability as individuals age.

As the medical community processes this new evidence, the key takeaway for older adults is to prioritize a balanced, nutrient-rich diet and engage in physical activities that promote strength. While the notion of a “supplement for every senior” may be waning, the importance of proactive, evidence-based strategies for maintaining bone health remains as critical as ever. The findings from this study could reshape the conversation around supplementation and encourage a more holistic approach to health in older adults, focusing on lifestyle changes that foster long-term well-being.

These insights are crucial for understanding the evolving landscape of bone health recommendations and the need for personalized approaches to supplementation and preventive care.

According to The BMJ, the implications of this study could lead to significant changes in clinical practice and public health guidelines regarding the use of calcium and vitamin D supplements among older adults.

Dr. Veena Shankaran has been appointed the inaugural holder of the Lert Family Endowed Chair at the Fred Hutch Cancer Center, focusing on the financial challenges faced by cancer patients.

Dr. Veena Shankaran, a prominent medical oncologist and healthcare economics researcher of Indian descent, has been named the inaugural holder of the newly established Lert Family Endowed Chair at the Fred Hutch Cancer Center in Seattle.

This appointment, part of the University of Washington Medicine’s cancer program, recognizes Shankaran’s extensive research into the financial hardships, often referred to as “financial toxicity,” that cancer treatments impose on patients and their families.

The endowed chair was created by Randy Lert, an esophageal cancer patient who received treatment under Shankaran’s care, and his wife, Joyce. Grateful for the honest and high-quality care they received, the Lerts established this chair to fund solutions for patients who encounter significant economic barriers when navigating a cancer diagnosis.

Shankaran’s academic credentials include a Bachelor of Arts in Philosophy from Dartmouth College and a Medical Degree from the University of Michigan Medical School. She completed her residency in internal medicine at the University of Michigan and pursued a fellowship in hematology-oncology at Northwestern University. Currently, she serves as a professor at both Fred Hutch and the University of Washington School of Medicine.

As co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), Shankaran was inspired to delve into health economics early in her career. Her focus shifted toward addressing structural inequities after encountering a patient who was secretly rationing his prescribed medication due to its cost, which adversely affected his treatment outcomes.

At HICOR, Shankaran and her research team integrate cancer registry data with healthcare claims and financial records to analyze how economic pressures influence patient survival and quality of life. Her work examines systemic issues, including medical debt, food insecurity, transportation challenges, and childcare needs.

Recently, her team investigated whether credit report data could assist healthcare providers in identifying financially distressed patients earlier than traditional surveys allow.

In addition, she leads a significant multi-site study through the SWOG Cancer Research Network, which found that nearly three-quarters of colon cancer patients experience severe financial distress during their treatment.

The flexible funding provided by the Lert Family Endowed Chair will enable Shankaran’s team to explore innovative, higher-risk ideas, pilot localized interventions, and expedite the process from concept to actionable results. It will also support the mentorship and training of future clinicians and health services researchers.

“Dr. Shankaran has been a leading force at Fred Hutch and nationally for decades,” said Fred Hutch President and Director Dr. Thomas J. Lynch Jr. He emphasized that her commitment to the economics of medicine ensures that scientific breakthroughs effectively translate into real-world benefits for patients.

For the Lert family, this gift represents an investment in systemic transformation. Randy Lert expressed that while he had the personal financial security to manage his illness, he hopes these funds will enhance healthcare delivery, allowing future patients facing similar diagnoses to achieve better outcomes.

According to The American Bazaar, Dr. Shankaran’s work is poised to make a significant impact on the lives of cancer patients grappling with financial challenges.

A new study suggests that the diabetes drug dapagliflozin may significantly reduce the risk of heart failure in individuals with specific genetic variants associated with cardiomyopathy.

A recent study published in Nature Medicine has revealed that dapagliflozin, a medication commonly used to treat type 2 diabetes, may help prevent heart failure in patients with genetic variants linked to cardiomyopathy, a progressive disease affecting the heart muscle.

Researchers from Harvard Medical School, Mass General Brigham, and MIT conducted the study using data from the DECLARE-TIMI 58 trial, which involved over 12,000 adults diagnosed with type 2 diabetes and at heightened risk for cardiovascular issues.

Among the participants, approximately 121 individuals carried inherited gene variants that could increase their likelihood of developing cardiomyopathy. The findings indicated that after a median follow-up of 4.2 years, dapagliflozin significantly reduced hospitalizations for heart failure among those with the genetic variants compared to those without.

While dapagliflozin was effective in lowering heart failure hospitalizations in both groups, the reduction was approximately eight times more pronounced in carriers of the genetic variant. Specifically, among the 82% of carriers without a prior history of heart failure, 12.8% in the placebo group developed heart failure, whereas no heart-failure events were reported among those receiving dapagliflozin.

Co-lead study author Dr. Shinwan Kany, a visiting scientist at the Cardiovascular Research Center with Mass General Brigham Heart and Vascular Institute and the Broad Institute, emphasized the implications of these findings for preventive care. “Historically, identifying a genetic variant for cardiomyopathy mostly meant telling a patient they were at high risk and not having a specific preventive therapy to offer,” he stated in a press release. “These data show we do have tools to lower risk in these individuals.”

Experts caution that while the results are promising, they require further validation due to the limited sample size of carriers in the study. Dr. Andrew Freeman, a cardiologist at National Jewish Health who was not involved in the research, described the findings as “important and provocative.” He noted that participants without a history of heart failure who took dapagliflozin were less likely to develop the condition, suggesting that SGLT2 inhibitors could serve as a preventive therapy for genetically high-risk individuals.

Freeman added, “This should be viewed as an exciting hypothesis-generating finding, not yet a practice-changing mandate for all patients with these genetic variants.” He highlighted that SGLT2 inhibitors are already recognized as foundational medications for cardiovascular and kidney protection.

These medications have been shown to reduce heart failure hospitalizations across a diverse range of patients, including those with diabetes, chronic kidney disease, and established heart failure. The current study introduces the potential for genetic information to help identify a subgroup of patients who may benefit significantly from early treatment.

Genetic testing for cardiomyopathy is often employed for diagnosis, family screening, and risk stratification. If future clinical trials confirm these findings, cardiologists may be able to utilize genetic screening to identify high-risk patients, monitor them more closely, and initiate treatments such as SGLT2 inhibitors before the onset of heart failure symptoms.

Freeman noted that heart failure does not always manifest with symptoms immediately; in some cases, the risk may be present years earlier due to inherited genetic factors. Preventive cardiology could play a crucial role in identifying high-risk patients before they experience symptoms such as shortness of breath, fluid retention, or the need for hospitalization.

As always, the decision to medicate should be made in consultation with a healthcare professional, particularly for individuals with a personal or family history of cardiovascular events. This study represents a significant step toward more personalized and effective preventive strategies in cardiology.

According to Fox News, the findings underscore the potential for integrating genetic insights into clinical practice, paving the way for more targeted interventions in the management of heart failure risk.

Researchers are uncovering new insights into the effects of GLP-1 medications like Ozempic and Wegovy on weight loss and overall health as their use becomes increasingly widespread.

As the popularity of GLP-1 medications such as Ozempic and Wegovy continues to rise, researchers are gaining unprecedented insights into their effects on weight loss and overall health. Tens of millions of individuals around the world are currently using these medications, prompting a unique real-time analysis of their impact on weight management, metabolism, and general well-being. This surge in usage has provided researchers with a substantial dataset that surpasses the findings typically available from controlled clinical trials.

The developments surrounding GLP-1 medications were discussed at the American Diabetes Association (ADA) Scientific Sessions conference held in New Orleans, where experts gathered to share their latest findings. Dr. Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity, emphasized that the rapid adoption of these drugs has led to an unprecedented learning curve for both practitioners and patients. “Usually when a new medicine happens, we have time to learn how to use it,” she said. “But with GLP-1 drugs, everyone is kind of iterating in real time.”

One of the key findings regarding the use of GLP-1 medications is the pattern of weight regain after discontinuation. Clinical trials have shown that patients typically lose between 15 to 20 percent of their body weight over approximately 72 weeks. However, real-world studies have presented a wider range, with weight loss varying from 8 to 17 percent depending on the specific drug and study parameters.

While many users experience weight regain after stopping the medication, some studies indicate that a significant portion of patients can maintain at least part of their weight loss. An analysis involving over 180,000 patients revealed that more than half who used semaglutide (the active ingredient in Wegovy) or tirzepatide (found in Zepbound) managed to either maintain their weight loss or even lose additional weight two years after discontinuation. Hamlet Gasoyan, a researcher at the Center for Value-Based Care Research at the Cleveland Clinic, explained that patients often adopt alternative strategies, such as rigorous exercise or bariatric surgery, to sustain their weight loss.

Notably, the effectiveness of GLP-1 medications varies among individuals. Current research indicates that approximately 10 percent of patients are classified as “non-responders,” losing less than 5 percent of their body weight. Conversely, a subset of patients, termed “super-responders,” lose significant amounts of weight in a relatively short timeframe, although the prevalence of this group remains unclear. Experts suggest that genetic factors and individual differences in the enjoyment derived from eating may contribute to these divergent responses.

While many patients report typical side effects such as nausea, fatigue, and gastrointestinal issues related to GLP-1 medications, the expansive user base has led to the emergence of additional, less common concerns. Social media has highlighted phenomena like “Ozempic breath” and “Ozempic face,” which refer to dehydration and aesthetic changes resulting from fat loss, respectively.

Dr. Scott Hagan, an associate professor of medicine at the University of Washington, noted that some patients have reported hair loss, potentially linked to rapid weight reduction. Moreover, some studies suggest a slight association between GLP-1 medications and the development of rare eye conditions, though causation has yet to be established. There is also concern about the potential for nutritional deficiencies among patients whose appetite is suppressed to extreme levels. While rare, there is a documented increase in the risk of pancreatitis associated with these medications.

The determination of the appropriate dosage for GLP-1 medications remains an area of active discussion among healthcare professionals. Patients typically begin treatment at a low dose, gradually increasing it over time. Although higher doses are often correlated with greater weight loss and improved blood sugar regulation, excessive dosing can suppress appetite to unhealthy levels, potentially leading to nutritional deficits and other adverse health outcomes.

As the popularity of GLP-1 drugs continues to rise, anecdotal evidence suggests that these medications may also influence patients’ personal lives and mental health. Some users report positive changes, such as increased confidence and enhanced physical activity, while others express concerns regarding diminished pleasure in eating and emotional well-being. Marie Spreckley, a researcher at the University of Cambridge, has noted that some patients feel emotionally flat and less connected to the social aspects of dining. These subjective experiences warrant further scientific inquiry.

Since the introduction of Ozempic to the market less than a decade ago, the landscape of weight management and metabolic health has begun to shift dramatically. As the body of research continues to grow, the healthcare community anticipates further revelations about the long-term implications of GLP-1 medications on health, lifestyle, and psychological well-being, according to Source Name.

The keto diet may offer significant benefits for individuals suffering from anorexia nervosa, according to new research from UC San Diego.

New research from the UC San Diego School of Medicine suggests that the ketogenic diet may help alleviate symptoms of anorexia nervosa. The study, published in the journal Nature, involved 22 women aged 18 to 45 who had a history of anorexia nervosa and a body mass index (BMI) above 17.5.

Anorexia nervosa (AN) is a serious psychiatric disorder characterized by severe food restriction and low body weight. Individuals with this condition often experience body dissatisfaction, an intense fear of eating, and a preoccupation with body shape and size, even after weight restoration.

The participants in the study adhered to a ketogenic therapy plan for 14 weeks, aiming for a diet composed of 70% fat, 20% protein, and 10% carbohydrates. The objective was to maintain weight while inducing nutritional ketosis, a metabolic state where the body produces and utilizes ketones for energy due to low carbohydrate intake.

Throughout the study, researchers monitored participants through ketone testing, weekly weight checks, symptom questionnaires, and nutritional and psychiatric support. Among the 18 participants who completed the study, improvements were noted in various areas related to eating disorder symptoms, including restraint, depression scores, and concerns regarding eating, shape, and weight.

Overall scores on the Eating Disorder Examination Questionnaire (EDE-Q) showed significant improvement, with 72% of participants scoring within the recovered or normal range. Importantly, participants’ body weight remained stable, and no BMI fell below the critical threshold of 17.5.

Those who continued to follow the ketogenic therapy three months post-intervention exhibited slightly better EDE-Q scores, indicating ongoing benefits from the dietary approach. The study authors concluded that ketogenic dietary therapy is “well-tolerated” and shows “potential efficacy” in reducing symptoms of anorexia nervosa among adults who are mildly underweight or weight-restored.

Despite these promising findings, the authors acknowledged that the small sample size, which predominantly consisted of White females, limits the generalizability of the results. They emphasized the need for future research to replicate these findings in more diverse populations and to incorporate objective assessments of brain function, such as metabolic PET imaging, to evaluate brain glucose metabolism.

Lead study author Dr. Guido Frank, a professor of psychiatry at UC San Diego School of Medicine, has dedicated over 25 years to studying and treating patients with anorexia. He initiated this study to expand treatment options for this high-risk population, stating that new approaches to anorexia nervosa are “urgently” needed.

Dr. Frank noted, “Our work with ketogenic therapy looks beyond standard therapies and potentially at the underlying physiology of the disorder.” He highlighted the growing evidence linking anorexia nervosa to neurometabolic dysfunction, expressing hope that direct metabolic intervention could help regulate neural function and address the psychological symptoms experienced by patients.

As the conversation around effective treatments for anorexia nervosa continues, this research opens the door to exploring alternative dietary interventions that may provide relief for those affected by this challenging condition, according to Fox News.

A new mRNA melanoma vaccine developed by Merck and Moderna has demonstrated significant long-term benefits, reducing the risk of cancer recurrence or death by nearly 50% over five years.

A novel mRNA melanoma vaccine, known as intismeran autogene, has shown promising results in reducing melanoma risk over a five-year period. This personalized cancer therapy, developed through a collaboration between Merck and Moderna, was presented during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.

The findings stem from the phase 2b KEYNOTE-942 study, which reported that the combination of intismeran autogene and the immunotherapy drug KEYTRUDA (pembrolizumab) reduced the risk of cancer recurrence or death by 49% compared to patients who received pembrolizumab alone.

Researchers analyzed data from 157 patients diagnosed with high-risk stage 3 and 4 melanoma, all of whom had undergone surgical removal of their tumors. Participants were divided into two groups: one received the combination therapy, while the other was treated solely with pembrolizumab. The results indicated that the benefits of the combination therapy were “sustained and durable over time.”

Intismeran autogene is engineered using mutations identified in a patient’s own tumor, aiming to educate the immune system on how to recognize and attack the cancer cells effectively.

According to the researchers, the personalized mRNA vaccine combined with KEYTRUDA is “well-tolerated” and has a “manageable” safety profile. Common side effects reported included fatigue, injection-site pain, chills, fever, and headache. Notably, there were no new long-term safety concerns or severe vaccine-related adverse events reported.

The combination therapy is currently undergoing evaluation in a phase 3 study, which represents the final confirmation stage before potential approval.

In a press release from Merck in January, Dr. Kyle Holen, senior vice president and head of development for oncology and therapeutics at Moderna, emphasized the significance of the data, stating it highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.” He added that the company continues to invest in its oncology platform due to encouraging outcomes that demonstrate mRNA’s potential in cancer care.

Dr. Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories, remarked on the importance of the findings, noting that many patients with stage 3 or 4 melanoma face a “significant risk of recurrence following surgery.” She described the demonstration of the longer-term potential of intismeran autogene and KEYTRUDA to reduce recurrence risk as a “meaningful milestone.”

The company has cited encouraging five-year follow-up data and is looking forward to results from the upcoming late-stage INTerpath trial, which will evaluate the combination therapy in several difficult-to-treat cancers.

As the field of cancer treatment continues to evolve, the promising results of the intismeran autogene vaccine may represent a significant step forward in the fight against melanoma and potentially other cancers, according to Fox News.

Dr. Samir M. Parikh, an esteemed Indian American nephrologist, has been appointed Chair of the Department of Internal Medicine at UT Southwestern Medical Center, effective June 15.

Dr. Samir M. Parikh, a prominent Indian American nephrologist, is set to assume the role of Chair of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas, starting June 15. In this prestigious position, he will oversee a department comprising nearly 900 faculty members and manage a residency program that ranks as the second largest in the nation.

Under Dr. Parikh’s leadership, the department will benefit from substantial funding, with more than $108 million allocated from the National Institutes of Health (NIH) for the fiscal year 2025. He will also hold the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy Sr. Chair in Molecular Nephrology, as announced in a university release.

Currently, Dr. Parikh serves as a Professor and Chief of the Division of Nephrology at UT Southwestern, a position he has held since joining the institution in 2021. He also has a secondary appointment in the Department of Pharmacology.

Dr. Parikh earned his bachelor’s degree in chemistry from Harvard College, graduating magna cum laude. He obtained his medical degree from Vanderbilt University and completed his internal medicine residency, along with research and clinical fellowships in nephrology, at Beth Israel Deaconess Medical Center. There, he was recognized as a Harvard Medical School Fellow in General Medicine.

His academic career began at Harvard, where he advanced to the position of Professor of Medicine. He also served as Co-Director of the Center for Vascular Biology Research and held the role of Associate Vice Chair for Research in the Department of Medicine at Beth Israel Deaconess.

In his clinical practice, Dr. Parikh specializes in acute kidney injury and chronic kidney disease. His research over the past two decades has concentrated on the mechanisms of aging in the vasculature, kidneys, and energy metabolism.

Dr. Parikh’s laboratory has garnered over $40 million in funding from the NIH and other sources, and his research findings have been published in prestigious journals, including *Science*, *Nature*, *Nature Medicine*, and *Cell Metabolism*.

In addition to his research and clinical work, Dr. Parikh is an elected member of several esteemed organizations, including the American Society for Clinical Investigation, the American Association of Physicians, and the American Clinical and Climatological Association.

His accolades include the NIH Outstanding Investigator Award, the Donald W. Seldin Young Investigator Award from both the American Society of Nephrology and the American Heart Association, as well as the STARs Award from the University of Texas System. Currently, he serves as the 59th President of the American Society of Nephrology (ASN).

During his presidency, ASN has made significant strides in advancing national research priorities through the Transforming Kidney Health Research initiative and has played a pivotal role in advocacy efforts that led to the passage of the Honoring our Living Donors (HOLD) Act.

Dr. W. P. Andrew Lee, Executive Vice President for Academic Affairs and Provost and Dean of UT Southwestern Medical School, expressed confidence in Dr. Parikh’s leadership. “Dr. Parikh’s commitment to all areas of our mission will further the Department of Internal Medicine and our institution’s national reputation for providing excellent clinical care, advancing meaningful research, and fostering a unique environment for biomedical education,” he stated.

Dr. Parikh’s appointment marks a significant milestone for UT Southwestern, as the institution continues to enhance its reputation as a leading center for medical education and research.

For more information, please refer to the official announcement from UT Southwestern.

Dr. Anushree Vichare has been appointed interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University, effective July 1.

Dr. Anushree Vichare, an accomplished Indian American researcher, has been named the interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University. She will officially assume her new role on July 1, succeeding Dr. Patricia “Polly” Pittman, who is retiring after co-founding the institute 11 years ago and serving as its director since 2020.

Vichare, an associate professor, began her academic journey in India, where she earned her Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from MGM Medical College. She later moved to the United States to further her education, obtaining a Master of Public Health in epidemiology and a PhD in Healthcare Policy and Research from Virginia Commonwealth University.

Her extensive academic portfolio reflects her training and expertise, focusing on how Medicaid policies influence healthcare access, utilization, and outcomes for low-income populations. At George Washington University, Vichare’s work in the Department of Health Policy and Management examines the composition, diversity, and geographic distribution of health workers and their impact on the quality of care available to underserved communities.

Dr. Pittman praised Vichare’s contributions, stating, “Anushree has been an integral part of the leadership team, has a deep commitment to our mission and work, and, importantly, is adored by everyone who has the chance to work with her.”

In her current role, Vichare serves as an investigator on several externally funded research initiatives at the Mullan Institute. Her recent scholarship includes analyzing maternal health services, evaluating care delivery for Medicaid beneficiaries diagnosed with cancer, and exploring the impact of patient-clinician concordance on primary care utilization.

In addition to her research, Vichare co-leads the Health Workforce Diversity Initiative under the Social Mission Alliance at the institute. Her previous experience in health policy includes serving as the director of quality improvement for the American Gastroenterological Association, where she specialized in developing clinical performance metrics and quality measures for colonoscopy care.

University officials have indicated that Vichare will guide the strategic operations of the institute while a national search for a permanent director is conducted. Her leadership is expected to continue advancing the institute’s mission of promoting health workforce equity.

According to a university release, Vichare’s appointment reflects the institution’s commitment to maintaining strong leadership during this transitional period.

Cancer survivors practicing yoga experience significant improvements in mood, anxiety, and fatigue, according to a recent clinical trial published in the Journal of Clinical Oncology.

Cancer survivors often face ongoing physical and emotional challenges long after their treatment has concluded. A recent clinical trial has found that yoga may play a crucial role in alleviating some of these issues, particularly insomnia, fatigue, and mood disturbances that many survivors endure after remission.

The study, funded by the National Cancer Institute, involved 410 participants, including 204 cancer survivors receiving standard survivorship care alone and 206 survivors who incorporated the Yoga for Cancer Survivors (YOCAS) program into their treatment. The majority of participants were female breast cancer survivors.

YOCAS is a four-week intervention that combines two types of yoga: hatha, which is more active and traditional, and restorative, which is gentler and more passive. Both styles emphasize slow movements, breathing exercises, and mindfulness, as noted by the American Society of Clinical Oncology (ASCO).

During the trial, participants in the YOCAS group practiced yoga for an average of 180 minutes each week across three sessions. At the end of the study, those in the YOCAS group reported significant improvements in mood, anxiety, and fatigue, while the standard care group showed no such benefits.

“Additionally, improvements in insomnia stemming from YOCAS yoga may be mediated by changes in overall mood disturbance and fatigue,” the researchers stated in their findings.

Dr. Fumiko Chino, a cancer researcher and associate professor in breast radiation oncology at MD Anderson Cancer Center, emphasized the importance of this study. “It offers survivors, who are likely already managing multiple medications, a non-pharmaceutical solution for reducing four different side effects at once,” she said.

Dr. Timothy Pearman, director of supportive oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, expressed that he was not surprised by the study’s results. “Yoga is one of the most widely studied and validated interventions for managing cancer-related fatigue, mood disturbance, and overall physical health,” he noted.

Pearman shared that his wife, Jenny Finkel, is a yoga teacher who received her continuing education at Duke University’s integrative medicine program, which specializes in yoga for cancer patients. He highlighted the accessibility of yoga, stating, “All you need is a mat and someone to show you how to do it.” He also mentioned that yoga is highly adaptable, making it suitable for individuals with significant physical impairments.

In addition to addressing mood and fatigue, Pearman pointed out that yoga can help mitigate other physical symptoms related to cancer treatment, such as osteoporosis, an increased risk of cardiac problems, and issues with balance and stamina.

Shari Botwin, a licensed clinical social worker based in Pennsylvania and a thyroid cancer survivor, has seen firsthand the transformative effects of yoga. Specializing in trauma recovery, she noted that many cancer survivors face emotional challenges, including depression and survivor’s guilt. Botwin believes that yoga not only provides physical relief but also fosters a supportive environment among peers, some of whom are also cancer thrivers.

Botwin added that yoga can assist survivors in reframing their thoughts, especially those who have lost parts of their bodies due to cancer. “It supports us in moving into a place of self-compassion rather than shame and self-hatred,” she explained.

While yoga has shown promising benefits, Pearman emphasized that almost any type of exercise can be advantageous for cancer survivors. He advises his patients to engage in activities they enjoyed prior to their diagnosis. Furthermore, he noted that free yoga classes tailored for cancer survivors are widely available through various non-profit organizations.

As research continues to unveil the benefits of yoga for cancer survivors, it becomes increasingly clear that this practice can play a vital role in enhancing the quality of life for those navigating the aftermath of cancer treatment, according to Fox News Digital.